Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome

Kirti Shetty, Kate Timmins, Colleen Brensinger, Emma E. Furth, Sushil Rattan, Weijing Sun, Mark Rosen, Michael Soulen, Abraham Shaked, K. Rajender Reddy, Kim M. Olthoff

Research output: Contribution to journalArticle

Abstract

Appropriate patient selection is crucial in ensuring acceptable outcomes from orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) has elected to prioritize HCC patients for OLT based on criteria of tumor burden. However, it is unclear whether these criteria correlate with outcome, or with the pathobiological features associated with tumor recurrence. Therefore, we analyzed 109 consecutive patients undergoing OLT for HCC at our center, to determine the utility of present selection criteria in predicting outcome. Pathologic tumor staging of the explanted liver was based on the American Tumor Study Group modified tumor node metastases (pTNM) classification system. Multifocality was defined as >4 tumor nodules on explant. Survival analysis was performed using Kaplan-Meier and Cox proportional hazards regression methods. At a median follow-up of 18.9 months, the overall mortality was 19% with 15 patients (14%) dying of recurrent HCC. Kaplan-Meier 1, 3 and 5-year survival rates were 89.5%, 68%, and 65%, respectively. Recurrence-free rates of 1, 3, and 5 years were 89%, 75%, and 65%, respectively. On univariate analysis, the factors found to be significantly associated with recurrence of HCC were explant features of macrovascular invasion, tumor size (per centimeter increase), pTNM stage(per 1-stage increase), and pre-transplant serum alphafetoprotein (AFP) > 300 ng/mL. In defining a threshold level, we found that explant tumor diameter ≥3 cm, and those tumors classified as at least pT3 on pathological examination, were significantly associated with recurrence (P = .01 and .03, respectively). Tumor size on explant was found to be strongly correlated with multifocality (P = .017) and vascular invasion (P = .02). Patients exceeding pathological UNOS criteria were 3.1 times more likely to have recurrence of HCC (P = .03). In conclusion, we found that tumor size appears to be a surrogate marker for negative pathobiological predictors of outcome, i.e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT.

Original languageEnglish (US)
Pages (from-to)911-918
Number of pages8
JournalLiver Transplantation
Volume10
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Liver Transplantation
Patient Selection
Hepatocellular Carcinoma
Neoplasms
Recurrence
Tumor Burden
Blood Vessels
Neoplasm Staging
Survival Analysis
Survival Rate
Biomarkers
Neoplasm Metastasis
Transplants
Mortality
Liver
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Shetty, K., Timmins, K., Brensinger, C., Furth, E. E., Rattan, S., Sun, W., ... Olthoff, K. M. (2004). Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transplantation, 10(7), 911-918. https://doi.org/10.1002/lt.20140

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. / Shetty, Kirti; Timmins, Kate; Brensinger, Colleen; Furth, Emma E.; Rattan, Sushil; Sun, Weijing; Rosen, Mark; Soulen, Michael; Shaked, Abraham; Reddy, K. Rajender; Olthoff, Kim M.

In: Liver Transplantation, Vol. 10, No. 7, 07.2004, p. 911-918.

Research output: Contribution to journalArticle

Shetty, K, Timmins, K, Brensinger, C, Furth, EE, Rattan, S, Sun, W, Rosen, M, Soulen, M, Shaked, A, Reddy, KR & Olthoff, KM 2004, 'Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome', Liver Transplantation, vol. 10, no. 7, pp. 911-918. https://doi.org/10.1002/lt.20140
Shetty, Kirti ; Timmins, Kate ; Brensinger, Colleen ; Furth, Emma E. ; Rattan, Sushil ; Sun, Weijing ; Rosen, Mark ; Soulen, Michael ; Shaked, Abraham ; Reddy, K. Rajender ; Olthoff, Kim M. / Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. In: Liver Transplantation. 2004 ; Vol. 10, No. 7. pp. 911-918.
@article{c1064624b57c4569b363a3b526c5768b,
title = "Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome",
abstract = "Appropriate patient selection is crucial in ensuring acceptable outcomes from orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) has elected to prioritize HCC patients for OLT based on criteria of tumor burden. However, it is unclear whether these criteria correlate with outcome, or with the pathobiological features associated with tumor recurrence. Therefore, we analyzed 109 consecutive patients undergoing OLT for HCC at our center, to determine the utility of present selection criteria in predicting outcome. Pathologic tumor staging of the explanted liver was based on the American Tumor Study Group modified tumor node metastases (pTNM) classification system. Multifocality was defined as >4 tumor nodules on explant. Survival analysis was performed using Kaplan-Meier and Cox proportional hazards regression methods. At a median follow-up of 18.9 months, the overall mortality was 19{\%} with 15 patients (14{\%}) dying of recurrent HCC. Kaplan-Meier 1, 3 and 5-year survival rates were 89.5{\%}, 68{\%}, and 65{\%}, respectively. Recurrence-free rates of 1, 3, and 5 years were 89{\%}, 75{\%}, and 65{\%}, respectively. On univariate analysis, the factors found to be significantly associated with recurrence of HCC were explant features of macrovascular invasion, tumor size (per centimeter increase), pTNM stage(per 1-stage increase), and pre-transplant serum alphafetoprotein (AFP) > 300 ng/mL. In defining a threshold level, we found that explant tumor diameter ≥3 cm, and those tumors classified as at least pT3 on pathological examination, were significantly associated with recurrence (P = .01 and .03, respectively). Tumor size on explant was found to be strongly correlated with multifocality (P = .017) and vascular invasion (P = .02). Patients exceeding pathological UNOS criteria were 3.1 times more likely to have recurrence of HCC (P = .03). In conclusion, we found that tumor size appears to be a surrogate marker for negative pathobiological predictors of outcome, i.e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT.",
author = "Kirti Shetty and Kate Timmins and Colleen Brensinger and Furth, {Emma E.} and Sushil Rattan and Weijing Sun and Mark Rosen and Michael Soulen and Abraham Shaked and Reddy, {K. Rajender} and Olthoff, {Kim M.}",
year = "2004",
month = "7",
doi = "10.1002/lt.20140",
language = "English (US)",
volume = "10",
pages = "911--918",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome

AU - Shetty, Kirti

AU - Timmins, Kate

AU - Brensinger, Colleen

AU - Furth, Emma E.

AU - Rattan, Sushil

AU - Sun, Weijing

AU - Rosen, Mark

AU - Soulen, Michael

AU - Shaked, Abraham

AU - Reddy, K. Rajender

AU - Olthoff, Kim M.

PY - 2004/7

Y1 - 2004/7

N2 - Appropriate patient selection is crucial in ensuring acceptable outcomes from orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) has elected to prioritize HCC patients for OLT based on criteria of tumor burden. However, it is unclear whether these criteria correlate with outcome, or with the pathobiological features associated with tumor recurrence. Therefore, we analyzed 109 consecutive patients undergoing OLT for HCC at our center, to determine the utility of present selection criteria in predicting outcome. Pathologic tumor staging of the explanted liver was based on the American Tumor Study Group modified tumor node metastases (pTNM) classification system. Multifocality was defined as >4 tumor nodules on explant. Survival analysis was performed using Kaplan-Meier and Cox proportional hazards regression methods. At a median follow-up of 18.9 months, the overall mortality was 19% with 15 patients (14%) dying of recurrent HCC. Kaplan-Meier 1, 3 and 5-year survival rates were 89.5%, 68%, and 65%, respectively. Recurrence-free rates of 1, 3, and 5 years were 89%, 75%, and 65%, respectively. On univariate analysis, the factors found to be significantly associated with recurrence of HCC were explant features of macrovascular invasion, tumor size (per centimeter increase), pTNM stage(per 1-stage increase), and pre-transplant serum alphafetoprotein (AFP) > 300 ng/mL. In defining a threshold level, we found that explant tumor diameter ≥3 cm, and those tumors classified as at least pT3 on pathological examination, were significantly associated with recurrence (P = .01 and .03, respectively). Tumor size on explant was found to be strongly correlated with multifocality (P = .017) and vascular invasion (P = .02). Patients exceeding pathological UNOS criteria were 3.1 times more likely to have recurrence of HCC (P = .03). In conclusion, we found that tumor size appears to be a surrogate marker for negative pathobiological predictors of outcome, i.e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT.

AB - Appropriate patient selection is crucial in ensuring acceptable outcomes from orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) has elected to prioritize HCC patients for OLT based on criteria of tumor burden. However, it is unclear whether these criteria correlate with outcome, or with the pathobiological features associated with tumor recurrence. Therefore, we analyzed 109 consecutive patients undergoing OLT for HCC at our center, to determine the utility of present selection criteria in predicting outcome. Pathologic tumor staging of the explanted liver was based on the American Tumor Study Group modified tumor node metastases (pTNM) classification system. Multifocality was defined as >4 tumor nodules on explant. Survival analysis was performed using Kaplan-Meier and Cox proportional hazards regression methods. At a median follow-up of 18.9 months, the overall mortality was 19% with 15 patients (14%) dying of recurrent HCC. Kaplan-Meier 1, 3 and 5-year survival rates were 89.5%, 68%, and 65%, respectively. Recurrence-free rates of 1, 3, and 5 years were 89%, 75%, and 65%, respectively. On univariate analysis, the factors found to be significantly associated with recurrence of HCC were explant features of macrovascular invasion, tumor size (per centimeter increase), pTNM stage(per 1-stage increase), and pre-transplant serum alphafetoprotein (AFP) > 300 ng/mL. In defining a threshold level, we found that explant tumor diameter ≥3 cm, and those tumors classified as at least pT3 on pathological examination, were significantly associated with recurrence (P = .01 and .03, respectively). Tumor size on explant was found to be strongly correlated with multifocality (P = .017) and vascular invasion (P = .02). Patients exceeding pathological UNOS criteria were 3.1 times more likely to have recurrence of HCC (P = .03). In conclusion, we found that tumor size appears to be a surrogate marker for negative pathobiological predictors of outcome, i.e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT.

UR - http://www.scopus.com/inward/record.url?scp=3242784151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242784151&partnerID=8YFLogxK

U2 - 10.1002/lt.20140

DO - 10.1002/lt.20140

M3 - Article

C2 - 15237377

AN - SCOPUS:3242784151

VL - 10

SP - 911

EP - 918

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 7

ER -